Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Calmy

Showing results (401-410 of 415) with videos related to

Pageof 42
Sort By:
HIV Medicine|September 29, 2023
Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohortFrédérique Hovaguimian, Roger D Kouyos, Katharina Kusejko, et al.
Nature|September 12, 2018
Tracing HIV-1 strains that imprint broadly neutralizing antibody responsesRoger D Kouyos, Peter Rusert, Claus Kadelka, et al.
Tobacco Induced Diseases|May 28, 2026
Acceptance and preferences for different nicotine substitute products to reduce tobacco smoking in people living with HIV: Results from an internal pilot study of a randomized trialChristof M Schönenberger, Stephanie Campos Ochoa, Benjamin Speich, et al.
The Lancet. HIV|June 27, 2025
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling studyAndrew N Phillips, Loveleen Bansi-Matharu, Joep J van Oosterhout, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 11, 2020
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort SettingLauren Greenberg, Lene Ryom, Gilles Wandeler, et al.
Trials|April 9, 2026
Offer of a menu of different nicotine substitute products to REduce Tobacco Use iN pEople living with HIV (RETUNE): a protocol for a pragmatic randomized trial within the Swiss HIV Cohort StudyChristof Manuel Schönenberger, Benjamin Speich, Elias R Zehnder, et al.
Lancet (London, England)|February 24, 2023
Mpox in people with advanced HIV infection: a global case seriesOriol Mitjà, Andrea Alemany, Michael Marks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2020
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency VirusLauren Greenberg, Lene Ryom, Bastian Neesgaard, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2017
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European studyLinda Wittkop, Julie Arsandaux, Ana Trevino, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
Pageof 42

Showing results (401-410 of 415) with videos related to

Sort By:
Pageof 42
HIV Medicine|September 29, 2023
Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohortFrédérique Hovaguimian, Roger D Kouyos, Katharina Kusejko, et al.
Nature|September 12, 2018
Tracing HIV-1 strains that imprint broadly neutralizing antibody responsesRoger D Kouyos, Peter Rusert, Claus Kadelka, et al.
Tobacco Induced Diseases|May 28, 2026
Acceptance and preferences for different nicotine substitute products to reduce tobacco smoking in people living with HIV: Results from an internal pilot study of a randomized trialChristof M Schönenberger, Stephanie Campos Ochoa, Benjamin Speich, et al.
The Lancet. HIV|June 27, 2025
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling studyAndrew N Phillips, Loveleen Bansi-Matharu, Joep J van Oosterhout, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 11, 2020
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort SettingLauren Greenberg, Lene Ryom, Gilles Wandeler, et al.
Trials|April 9, 2026
Offer of a menu of different nicotine substitute products to REduce Tobacco Use iN pEople living with HIV (RETUNE): a protocol for a pragmatic randomized trial within the Swiss HIV Cohort StudyChristof Manuel Schönenberger, Benjamin Speich, Elias R Zehnder, et al.
Lancet (London, England)|February 24, 2023
Mpox in people with advanced HIV infection: a global case seriesOriol Mitjà, Andrea Alemany, Michael Marks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2020
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency VirusLauren Greenberg, Lene Ryom, Bastian Neesgaard, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2017
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European studyLinda Wittkop, Julie Arsandaux, Ana Trevino, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
Pageof 42